AMR Action Fund

AMR Action Fund investment thesis

As a microbiologist, venture investor, and executive, Henry Skinner, PhD, MBE, MJur, has spent his career working to overcome the scientific and economic challenges associated with antimicrobial drug development. His cross-disciplinary expertise has been essential to shaping the AMR Action Fund’s investment portfolio and policy priorities, with an emphasis on issues pertaining to R&D, innovative financing, and equitable access. Dr. Skinner is regularly sought out for high-level speaking engagements to discuss the global threat of AMR and is frequently featured in the media, including The New York Times , The Wall Street Journal , Bloomberg News , and the Financial Times . He has written widely on the topic in scholarly publications and the popular press, including Nature Medicine , Harvard

AMR Action Fund team (3)

Partners and principals at AMR Action Fund:

• Martin Heidecker — sweet spot $1.5M
• Carly Levine — sweet spot $1.5M
• Henry Skinner — sweet spot $1.5M

AMR Action Fund portfolio companies

Companies listed on AMR Action Fund's public materials include: Skip to main content, About, Our Mission, Threat of AMR, Access and Appropriate Use Principles, Our Investors, Team, Investments, How We Invest, Our Portfolio, Get On Our Radar, News, Connect, Get on our radar, A Clear Scope, An Expert SAB, A Global Presence, Advancing New Antimicrobials to Patients, READ SUMMARY +, Visit Website, VISIT WEBSITE, Latest, Japan Disclaimer.

Is AMR Action Fund a fit for your round?

Upload your pitch deck and see whether anyone at AMR Action Fund appears in your top matches.